Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2022

Feb 10, 2022

30718_dirs_2022-02-10_e6a29b96-fd1b-4045-9ef5-8e58a5db7099.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2022-02-08

Reporting Person: Kelderman Kim (Pres. Diagnostics & Genom)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-02-08 Common Stock M 1989 $150.78 Acquired 1989 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-02-08 Stock Option (Right to Buy) $150.78 M 1989 Disposed 2025-05-01 Common Stock (1989) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $177.3200 2025-08-08 Common Stock (12044) 12044 Direct
Stock Option (Right to Buy) $177.3200 2025-08-08 Common Stock (9033) 9033 Direct
Stock Option (Right to Buy) $190.4100 2026-08-07 Common Stock (11961) 11961 Direct
Restricted Stock Units $ Common Stock (2363) 2363 Direct
Stock Option (Right to Buy) $190.4100 2026-08-07 Common Stock (15948) 15948 Direct
Restricted Stock Units $ Common Stock (2015) 2015 Direct
Stock Option (Right to Buy) $267.8700 2027-08-05 Common Stock (8991) 8991 Direct
Stock Option (Right to Buy) $267.8700 2027-08-05 Common Stock (11988) 11988 Direct
Stock Option (Right to Buy) $267.8700 2027-08-05 Common Stock (8325) 8325 Direct
Stock Option (Right to Buy) $267.8700 2027-08-05 Common Stock (8325) 8325 Direct
Restricted Stock Units $ Common Stock (1245) 1245 Direct
Stock Option (Right to Buy) $481.8200 2028-08-06 Common stock (6486) 6486 Direct
Stock Option (Right to Buy) $481.8200 2028-08-06 Common Stock (4864) 4864 Direct

Footnotes

F1: Options to purchase 2,500 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.

F2: Options to purchase 3,011 shares vest on each of 8/8/2019, 8/8/2020, 8/8/2021 and 8/8/2022.

F3: Fully exercisable.

F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F5: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F6: Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023.

F7: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F8: Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024.

F9: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

F10: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

F11: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F12: Options to purchase 1,621 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 1,622 shares vest on each of 8/6/2024 and 8/6/2025.